Replies to post #355043 on NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

Admin must've missed NWBO's fax about their therapy. Eye roll.

No reason it couldn't be done second time around.

[BWIS]

I think the girl from the Britain, Kat had multiple surgeries. I think Lykiri might know about her.

When do doctors know that it is GBM?

[Hopeforthefuture3]

Try calling Dave Innes. He will probably give you the number to Sue Goldman to see if any potential treatment
Good luck

[biosectinvestor]

Kat got hers from the recurrent tumor. They could only remove approximately 80% on that surgery and, of course, all signs of it eventually disappeared.

[Basin Street Blues]

Thanks to everyone that replied.

[Evaluate]

you wrote:

So I know someone who was diagnosed with nGMB in December , They immediately had surgery but of course the tumour wasn’t saved ...do we know of anyone that been treated with dcvax made from the tumour once it came back ??

Below could be of interest:
https://www.mdpi.com/2072-6694/13/1/47
Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Cancers 2021, 13(1), 47; https://doi.org/10.3390/cancers13010047
includes:

Dendritic cells (DCs) are professional immune cells presenting antigens for T cells. They induce adaptive immunity [78].
Noteworthily, a phase III clinical trial evaluating autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L, Northwestern Biotherapeutics Inc., Bethesda, Rockville, MD, USA) plus the standard of care showed encouraging results and a satisfactory safety profile in newly diagnosed GBM [79].
In the same line, an ongoing phase III clinical trial investigating autologous dendritic cell vaccines (i.e., ADCTA autologous dendritic cells co-cultured with autologous tumor antigen) suggests specific immune response in rGBM(NCT04277221) [80]

and

7. Conclusions
In recent years, a multitude of novel therapies have shown promising signs of efficacy in rGBM patients. Precision medicine such as the combination of dabrafenib and trametinib in BRAF V600E mutated gliomas, or other tyrosine kinase inhibitors such as regorafenib or NTRK inhibitors, may be used in selected patients.
Checkpoint inhibitors such as nivolumab and pembrolizumab failed to improve overall survival, yet their association
with tyrosine kinase inhibitors seems more promising.
However, the responses were observed on a highly selected and very limited patient population. Future work should therefore first focus on better understanding the potential responses and identifying the patient population most likely to benefit. In the longer term, an enhanced understanding of the underlying molecular characteristics and genetic landscape of rGBM is required to identify novel (targeted) therapies and combination regimens.